Thus, whilst potential inhibition of the PI3Kδ, ERK1/2 and NFκB effector molecules may be of some benefit as a therapeutic strategy asthma, it is more likely that a greater therapeutic margin would be gained by blocking upstream targets such SFK or EGFR. Here, MAPK3 is linked to asthma.